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Purpose: Gemcitabine and cisplatin (GC) has beenwidely used for advanced
and metastatic urothelial carcinoma (UC). However, resistance to this rem-
edyhas been noticed.Wehave demonstrated that increase of TG-interacting
factor (TGIF) in specimens is associated withworse prognosis of upper tract
UC (UTUC) patients. The roles of TGIF in the gemcitabine resistance of UTUC
and a promising therapeutic strategy to UC were explored.
Materials and methods: Specimens of 23 UTUC patients who received GC
systemic chemotherapy were collected to evaluate the alterations of TGIF
in the resistance to the remedy by using immunohistochemistry. In vitro
characterizations of mechanismsmediating TGIF in gemcitabine resistance
were conducted by analyzing NTUB1 cells and their gemcitabine-resistant
sublines, NGR cells.
Results and conclusions: Increased TGIF and p-AKTSer473 are signiﬁcantly
associated with chemo-resistance, poor progression-free survival, and
higher cancer-related deaths of UTUC patients. Higher increases of TGIF, p-
AKTSer473, and invasive ability were demonstrated in NGR cells. Over-
expression of TGIF in NTUB1 cells upregulated p-AKTSer473 activation,
migration ability, and attenuated cellular sensitivity to gemcitabine.
Knockdown of TGIF in NGR cells downregulated p-AKTSer473 activation,
migration ability, and enhanced cellular sensitivity to gemcitabine. In
addition, histone deacetylases inhibitor trichostatin A (TSA) can inhibit
TGIF, p-AKTSer473 expression and migration ability. Synergistic effects of
gemcitabine and TSA on NGR cells were also demonstrated. Collectively,
TGIF contributes to the gemcitabine resistance of UTUC via AKT activation.
Combined treatment with gemcitabine and TSA might be a promising
therapeutic remedy to improve the gemcitabine resistance of UC.
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* Corresponding author.Purpose: Hepatoma-derived growth factor (HDGF) is a nucleus targeted
growth factor, it has been reported to exertmitogenic effects on several types
of cells and elevated in various types of cancers suggesting an important role
in the development and progression of cancers. Our study was designed to
elucidate the correlation of HDGF expression and prognosis in patients with
upper urinary tract urothelial carcinoma (UTUC). The relatedmechanisms of
HDGF involved were investigated using urothelial cancer cell lines.
Patients and methods: One hundred and ﬁfty-eight UTUC specimens
were analyzed for HDGF by immunohistochemistry. HDGF expression in
urothelial cancer cell lines was analyzed by RT-PCR and western blotting.
In vitro characterizations of the cellular function of recombinant HDGF in
epithelial-mesenchymal transition (EMT) and tumorigenic behaviors were
performed by trans-well assay and colony formation assay, respectively.
Results and conclusion: Overexpression of HDGFwas present in 74 patients
(46.8%). A positive HDGF expressionwas signiﬁcantly associated with higher
disease progression (p¼ 0.036) and cancer-related death rates (p¼ 0.001). In
vitro study showed that overexpression of HDGF in non-invasive UC cells
could signiﬁcantly increase their cellular proliferation, colonies formation,
and migration/invasion ability through the PI3K/AKT pathway. In contrast,
knockdown of HDGF high expression UC cells with its speciﬁc shRNA
inhibited the growth ability using colonies formation experiments. These
results indicated that HDGF overexpression is associated with aggressive
biological behavior of UC cells via the PI3K/AKT pathway. In conclusion, our
study shown that HDGF is participated in UC disease progression processes.
HDGF can be a potential prognostic prediction biomarker for patients with
invasive UTUC post-operatively. Further identiﬁcation of the molecular
mechanisms involved and searching for speciﬁc targets related are warranted
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Purpose: This study is designed to evaluate the estimated glomerular
ﬁltration rate (eGFR) changes in patients undergoing radical nephro-ure-
terectomy (RNU) for upper tract urothelial carcinoma (UTUC).
Materials and methods: We retrospectively reviewed our patients with
upper urinary tract TCC undergone nephroureterectomy from 2007 to
2012. Only patients with upper urinary tract transitional cell carcinoma
(TCC) were enrolled in our study.We exclused the patients with end-stage-
renal disease. Total 72 patients had completed follow up for three years
after nephroureterectomy. The estimated glomerular ﬁltration rate (eGFR)
was calculated using the modiﬁed glomerular ﬁltration rate estimating
equation: eGFR (mL/min/1.73 m2) ¼ 175  Scr1.234  age0.179 ( 0.79 if
female). We compared eGFR before surgery and one year after surgery, two
years after surgery, and three years after surgery.
Results: Overall 72 patients were included in the study. The median age at
surgery was 66.46 (46e86) years. 31 patients (44%) had a preoperative
eGFRS 60mL/min per 1.73 m2 and 53 (75%) had an eGFRS 45mL/min per
1.73 m2. The preoperative CKD stage distribution was: CKD I (n ¼ 4, 5.5%),
CKD II (n ¼ 27, 37.5%), CKD III (n ¼ 33, 46%), and CKD IV (n ¼ 8, 11.1%). After
RNU,15 patients (20.8%) had a postoperative eGFRS 60mL/min per 1.73m2
and41 (56.9%)had aneGFRS45mL/minper1.73m2. Thepostoperative CKD
stages distributionwas: CKD I (n¼ 1,1%), CKD II (n¼ 14,19%), CKD III (n¼ 46,
64%), CKD IV (n¼ 5, 7%) and CKDV (n¼ 6, 8.3%). Comparison of preoperative
and postoperative Scr levels for each patient showed a mean difference of
0.44 mg/dL (P < 0.001), which represents a median (IQR) increase of 27.2%.
On similaranalysisperformed for eGFR,we foundameandifferencebetween
preoperative and postoperative eGFRof 10.8mL/min per 1.73m2 (P< 0.001),
which represents a median (IQR) decrease of 18.2 %. 3 years after RNU, 14
patients (19%) had a postoperative eGFRS 60 mL/min per 1.73 m2 and 37
(51.4%) had an eGFR S 45 mL/min per 1.73 m2. The long-term CKD stages
distributionwas: CKD I (n¼ 0, 0%), CKD II (n¼ 14,19%), CKD III (n¼ 38, 53%),
CKD IV (n ¼ 11, 22.2%) and CKD V (n ¼ 9, 12.5%). The eGFR decreased within
years as 58.06, 47.28, 45.68, and 41.91 mL/min per 1.73 m2 (P < 0.001).
Conclusions: TCCs located in the upper urinary tract had negative impact
on the ipsilateral renal function. eGFR was relatively low and furthermore,
it signiﬁcantly decreased within years after RNU.
